In the liver, this manifests as metabolic disruption, NAFLD development, insulin resistance [60,61], and chronic NF-κB-mediated inflammation [251], and in the pancreas—local inflammation [257] and increased risk of metabolic disorders and diabetes upon PET-MPs exposure with characteristic transcriptomic shifts [258]. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.